Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?

Phase 2

Completed

• Conditions: Blood Glucose; Type-2 Diabetes; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12610000185066
• Lead Sponsor: Adam Deane

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Inclusion criteria
Critically ill patients with pre-existing type- 2 diabetes (not requiring insulin prior to hospital) and who require artificial ventilation
Likely to be ventilated for >48hrs
Suitable to receive enteral nutrition via naso-jejunal feeding tube

Exclusion Criteria

Age <18 Age>85 Pregnancy Small bowel obstruction History of insulin-requiring diabetes Previous surgery on the oesophagus, stomoach or duodenum Any gastrointestinal surgery on this admission

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood glucose during small intestinal feeding (as measured as Area under the curve)[4 hours (30-270 min)]

Secondary Outcome Measures

Name	Time	Method
Blood glucose (time above 10 mmol/l)[actual time. Blood glucose will be monitored every 15 minutes throughout the study period];Peak blood glucose[actual time between t=30-270 min];Regulatory and counter-regulatory hormone release. Measured using plasma Insulin and glucagon concentrations[Every 30 minutes for the first 150 minutes and thereafter every 60 minutes until 270 min]